Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Vitamin K Supplementation in Chronic Kidney Disease Patients: Where is the Evidence?

Author(s): Stefanos Roumeliotis*, Vassilios Liakopoulos and Leon J. Schurgers

Volume 20, Issue 2, 2022

Published on: 24 February, 2022

Page: [121 - 126] Pages: 6

DOI: 10.2174/1570161120666220209145341

conference banner
Abstract

Vascular calcification (VC) is highly prevalent in Chronic Kidney Disease (CKD) patients, progresses gradually with deterioration of kidney function and is a strong, independent predictor of cardiovascular (CV) mortality. Matrix Gla Protein (MGP), the most potent inhibitor of VC, requires vitamin K as a co-factor to become biologically active. Accumulating epidemiological data have associated vitamin K depletion with VC progression and CV outcomes. CKD patients are characterized by poor vitamin K status and at the same time, pronounced CV calcification. In early and advanced CKD, including end-stage kidney disease, exogenous supplementation of vitamin K (especially with menaquinone 7, its most bioavailable form) might decrease the inactive form of MGP (dephosphorylated, uncarboxylated MGP) and probably retard the progression or even reverse VC. Here, we focus and discuss the interventional human studies of vitamin K supplementation in CKD patients and suggest future directions in this area of interest.

Keywords: Chronic kidney disease, dephosphorylated uncarboxylated MGP, end stage kidney disease, matrix gla protein, vascular calcification, vitamin K2.

« Previous Next »
Graphical Abstract

[1]
Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16(2): 489-95.
[http://dx.doi.org/10.1681/ASN.2004030203] [PMID: 15590763]
[2]
Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63(3): 1121-9.
[http://dx.doi.org/10.1046/j.1523-1755.2003.00838.x] [PMID: 12631096]
[3]
Schlieper G, Krüger T, Djuric Z, et al. Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int 2008; 74(12): 1582-7.
[http://dx.doi.org/10.1038/ki.2008.458] [PMID: 18800030]
[4]
Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. Biomarkers of vascular calcification in serum. Adv Clin Chem 2020; 98: 91-147.
[http://dx.doi.org/10.1016/bs.acc.2020.02.004] [PMID: 32564789]
[5]
Schlieper G, Westenfeld R, Brandenburg V, Ketteler M. Inhibitors of calcification in blood and urine. Semin Dial 2007; 20(2): 113-21.
[http://dx.doi.org/10.1111/j.1525-139X.2007.00257.x] [PMID: 17374084]
[6]
Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386(6620): 78-81.
[http://dx.doi.org/10.1038/386078a0] [PMID: 9052783]
[7]
Roumeliotis S, Roumeliotis A, Stamou A, et al. The association of dp-ucMGP with cardiovascular morbidity and decreased renal function in diabetic chronic kidney disease. Int J Mol Sci 2020; 21(17): E6035.
[http://dx.doi.org/10.3390/ijms21176035] [PMID: 32839405]
[8]
Roumeliotis S, Roumeliotis A, Panagoutsos S, et al. Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy. J Diabetes Complications 2017; 31(10): 1527-32.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.06.012] [PMID: 28734846]
[9]
Roumeliotis S, Dounousi E, Eleftheriadis T, Liakopoulos V. Association of the inactive circulating matrix GLA protein with vitamin K intake, calcification, mortality, and cardiovascular disease: A review. Int J Mol Sci 2019; 20(3): E628.
[http://dx.doi.org/10.3390/ijms20030628] [PMID: 30717170]
[10]
Schlieper G, Westenfeld R, Krüger T, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011; 22(2): 387-95.
[http://dx.doi.org/10.1681/ASN.2010040339] [PMID: 21289218]
[11]
Delanaye P, Krzesinski JM, Warling X, et al. Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol 2014; 15: 145.
[http://dx.doi.org/10.1186/1471-2369-15-145] [PMID: 25190488]
[12]
Puzantian H, Akers SR, Oldland G, et al. Circulating dephospho-uncarboxylated matrix Gla-protein is associated with kidney dysfunction and arterial stiffness. Am J Hypertens 2018; 31(9): 988-94.
[http://dx.doi.org/10.1093/ajh/hpy079] [PMID: 29788226]
[13]
Thamratnopkoon S, Susantitaphong P, Tumkosit M, et al. Correlations of plasma desphosphorylated uncarboxylated matrix Gla protein with vascular calcification and vascular stiffness in chronic kidney disease. Nephron 2017; 135(3): 167-72.
[http://dx.doi.org/10.1159/000453368] [PMID: 27951533]
[14]
Card DJ, Shearer MJ, Schurgers LJ, Gomez K, Harrington DJ. What’s in a name? The pharmacy of vitamin K. Br J Haematol 2016; 174(6): 989-90.
[http://dx.doi.org/10.1111/bjh.13828] [PMID: 26492096]
[15]
Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study. J Nutr 2004; 134(11): 3100-5.
[http://dx.doi.org/10.1093/jn/134.11.3100] [PMID: 15514282]
[16]
Riphagen IJ, Keyzer CA, Drummen NEA, et al. Prevalence and effects of functional vitamin K insufficiency: The PREVEND study. Nutrients 2017; 9(12): E1334.
[http://dx.doi.org/10.3390/nu9121334] [PMID: 29292751]
[17]
Cheung CL, Sahni S, Cheung BM, Sing CW, Wong IC. Vitamin K intake and mortality in people with chronic kidney disease from NHANES III. Clin Nutr 2015; 34(2): 235-40.
[http://dx.doi.org/10.1016/j.clnu.2014.03.011] [PMID: 24745600]
[18]
Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. Vitamin K for the treatment of cardiovascular disease in end-stage renal disease patients: Is there hope? Curr Vasc Pharmacol 2021; 19(1): 77-90.
[http://dx.doi.org/10.2174/1570161118666200320111745] [PMID: 32196451]
[19]
Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109(7): 2823-31.
[http://dx.doi.org/10.1182/blood-2006-07-035345] [PMID: 17138823]
[20]
Kaesler N, Magdeleyns E, Herfs M, et al. Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney Int 2014; 86(2): 286-93.
[http://dx.doi.org/10.1038/ki.2013.530] [PMID: 24429407]
[21]
Spronk HM, Soute BA, Schurgers LJ, Thijssen HH, De Mey JG, Vermeer C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res 2003; 40(6): 531-7.
[http://dx.doi.org/10.1159/000075344] [PMID: 14654717]
[22]
Scheiber D, Veulemans V, Horn P, et al. High-dose menaquinone-7 supplementation reduces cardiovascular calcification in a murine model of extraosseous calcification. Nutrients 2015; 7(8): 6991-7011.
[http://dx.doi.org/10.3390/nu7085318] [PMID: 26295257]
[23]
Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. Am J Kidney Dis 2012; 59(2): 186-95.
[http://dx.doi.org/10.1053/j.ajkd.2011.10.041] [PMID: 22169620]
[24]
Caluwé R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2 supplementation in haemodialysis patients: A randomized dose-finding study. Nephrol Dial Transplant 2014; 29(7): 1385-90.
[http://dx.doi.org/10.1093/ndt/gft464] [PMID: 24285428]
[25]
Aoun M, Makki M, Azar H, Matta H, Chelala DN. High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: Risk factors and response to vitamin K2, A pre-post intervention clinical trial. BMC Nephrol 2017; 18(1): 191.
[http://dx.doi.org/10.1186/s12882-017-0609-3] [PMID: 28592319]
[26]
Kazzi NJ, Ilagan NB, Liang K-C, Kazzi GM, Grietsell LA, Brans YW. Placental transfer of vitamin K1 in preterm pregnancy. Obstet Gynecol 1990; 75(3 Pt 1): 334-7.
[PMID: 2304704]
[27]
Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, et al. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5. Pol Arch Med Wewn 2015; 125(9): 631-40.
[http://dx.doi.org/10.20452/pamw.3041] [PMID: 26176325]
[28]
Mansour AG, Hariri E, Daaboul Y, et al. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial. J Am Soc Hypertens 2017; 11(9): 589-97.
[http://dx.doi.org/10.1016/j.jash.2017.07.001] [PMID: 28756183]
[29]
Witham MD, Lees JS, White M, et al. Vitamin K supplementation to improve vascular stiffness in CKD: The K4Kidneys randomized controlled trial. J Am Soc Nephrol 2020; 31(10): 2434-45.
[http://dx.doi.org/10.1681/ASN.2020020225] [PMID: 32817311]
[30]
Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost 2015; 113(5): 1135-44.
[http://dx.doi.org/10.1160/TH14-08-0675] [PMID: 25694037]
[31]
Oikonomaki T, Papasotiriou M, Ntrinias T, et al. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: A 1-year follow-up randomized trial. Int Urol Nephrol 2019; 51(11): 2037-44.
[http://dx.doi.org/10.1007/s11255-019-02275-2] [PMID: 31529295]
[32]
Levy-Schousboe K, Frimodt-Møller M, Hansen D, et al. Vitamin K supplementation and arterial calcification in dialysis: Results of the double-blind, randomised, placebo-controlled renakvit trial. Clin Kidney J 2021; 14(9): 2114-3.
[33]
Neradova A, Schumacher SP, Hubeek I, Lux P, Schurgers LJ, Vervloet MG. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. BMC Nephrol 2017; 18(1): 149.
[http://dx.doi.org/10.1186/s12882-017-0560-3] [PMID: 28464802]
[34]
De Vriese AS, Caluwé R, Pyfferoen L, et al. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: The Valkyrie Study. J Am Soc Nephrol 2020; 31(1): 186-96.
[http://dx.doi.org/10.1681/ASN.2019060579] [PMID: 31704740]
[35]
Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Vascular calcification in chronic kidney disease: The role of vitamin K- dependent matrix Gla protein. Front Med (Lausanne) 2020; 7: 154.
[http://dx.doi.org/10.3389/fmed.2020.00154] [PMID: 32391368]
[36]
Lees JS, Mangion K, Rutherford E, et al. Vitamin K for kidney transplant organ recipients: investigating vessel stiffness (ViKTORIES): Study rationale and protocol of a randomised controlled trial. Open Heart 2020; 7(2): e001070.
[http://dx.doi.org/10.1136/openhrt-2019-001070] [PMID: 32675297]
[37]
Holden RM, Booth SL, Day AG, et al. Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: Rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health Dis 2015; 2(1): 17.
[http://dx.doi.org/10.1186/s40697-015-0053-x] [PMID: 26075081]
[38]
Krueger T, Schlieper G, Schurgers L, et al. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): A rationale and study protocol. Nephrol Dial Transplant 2014; 29(9): 1633-8.
[http://dx.doi.org/10.1093/ndt/gft459] [PMID: 24285427]
[39]
Roumeliotis S, Roumeliotis A, Eleftheriadis T, Liakopoulos V. Letter to the Editor regarding “Six months vitamin K treatment does not affect systemic arterial calcification or bone mineral density in diabetes mellitus 2”. Eur J Nutr 2021; 60(3): 1701-2.
[http://dx.doi.org/10.1007/s00394-020-02469-w] [PMID: 33532875]
[40]
Roumeliotis S, Roumeliotis A, Gorny X, Mertens PR. Could antioxidant supplementation delay progression of cardiovascular disease in end-stage renal disease patients? Curr Vasc Pharmacol 2021; 19(1): 41-54.
[http://dx.doi.org/10.2174/1570161118666200317151553] [PMID: 32183680]

Rights & Permissions Print Cite
Article Metrics
33
1
© 2024 Bentham Science Publishers | Privacy Policy